Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer

Head & Neck ◽  
2014 ◽  
Vol 37 (5) ◽  
pp. 727-734 ◽  
Author(s):  
Victor D. Martinez ◽  
Emily A. Vucic ◽  
Kelsie L. Thu ◽  
Larissa A. Pikor ◽  
Stephen Lam ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Ubiquitin Ligase ◽  
Poor Prognosis ◽  
E3 Ubiquitin Ligase ◽  
Ubiquitin Ligase Complex ◽  
Genetic Mechanisms ◽  
Complex Components

scholarly journals Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer

2017 ◽  
Vol 353 (1) ◽  
pp. 46-53 ◽  
Author(s):  
Meng Xiao ◽  
Ming Yan ◽  
Jianjun Zhang ◽  
Qin Xu ◽  
Shengcai Qi ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Ubiquitin Ligase ◽  
E3 Ubiquitin Ligase ◽  
Related Protein

Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.

1989 ◽  
Vol 7 (6) ◽  
pp. 761-768 ◽  
Author(s):  
E E Vokes ◽  
W R Panje ◽  
R L Schilsky ◽  
R Mick ◽  
A M Awan ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Poor Prognosis ◽  
Local Therapy ◽  
Complete Response ◽  
Synergistic Activity ◽  
Dose Levels ◽  
Concomitant Radiotherapy

Hydroxyurea and fluorouracil (5-FU) are active cytotoxic drugs in head and neck cancer and have shown synergistic activity in vitro. Both drugs also act as radiosensitizers. Therefore, we administered radiotherapy at daily fractions of 180 to 200 cGy with simultaneous continuous infusion 5-FU at 800 mg/m2/d and escalating daily doses of hydroxyurea for five days. Cycles were repeated every other week until completion of radiotherapy. Thirty-nine inoperable patients were treated at six dose levels of hydroxyurea ranging from 500 mg to 3,000 mg orally daily. Little effect of hydroxyurea on the WBC or platelet count was noted in patients receiving less than 2,000 mg daily, whereas both parameters decreased progressively in patients receiving 2,000 mg daily or more. Mucositis occurred at all dose levels, requiring frequent dose reduction of 5-FU; however, in patients receiving a daily hydroxyurea dose of 2,000 mg or less, the median weekly 5-FU dose administered was 1,725 mg/m2 (86% of the intended 5-FU dose), whereas at daily hydroxyurea doses exceeding 2,000 mg, the median weekly 5-FU dose decreased to 1,133 mg/m2 (57%) (P = .001). Of 15 evaluable patients with recurrent disease after prior local therapy only one failed to respond; six had a complete response (CR), and eight a partial response (PR). Of 17 evaluable patients without prior local therapy, 12 had a CR, with no patient developing recurrence in the irradiated field to date; five patients had a PR. We conclude that the recommended dose of hydroxyurea in this regimen is 2,000 mg daily. That dose will cause mild to moderate myelosuppression and will allow for delivery of greater than 80% of the intended 5-FU dose. The activity of this regimen in poor-prognosis head and neck cancer exceeds 90%; its further investigation in previously untreated patients is warranted.

Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.

1994 ◽  
Vol 12 (11) ◽  
pp. 2351-2359 ◽  
Author(s):  
E E Vokes ◽  
D J Haraf ◽  
R Mick ◽  
J M McEvilly ◽  
R R Weichselbaum
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Poor Prognosis ◽  
Locoregional Control ◽  
Cumulative Toxicity ◽  
Life Threatening ◽  
Group 2 ◽  
Concomitant Radiotherapy ◽  
Group 1

PURPOSE We previously demonstrated high locoregional control rates in patients with poor-prognosis head and neck cancer using fluorouracil (5-FU), hydroxyurea (HU), and concomitant radiotherapy (FHX). In two trials reported here, we added cisplatin with and without granulocyte colony-stimulating factor (G-CSF) to 5-FU, HU, and concomitant radiotherapy. PATIENTS AND METHODS Eligible patients had failed to respond to prior local therapy (group 1); previously untreated patients with unresectable and/or metastatic disease and a projected 2-year survival rate less than 10% were also eligible (group 2). Chemoradiotherapy consisted of 1.8 to 2.0 Gy on days 1 to 5 with simultaneous infusional 5-FU at 800 mg/m2/d and HU administered every 12 hours for 11 doses at escalating doses. Cisplatin was administered at 100 mg/m2 during every other cycle. Cycles were repeated every 14 days until completion of radiotherapy. In study 2, G-CSF was added on days 6 to 13 at 5 micrograms/kg/d. RESULTS Acute and cumulative myelosuppression limited the feasibility of adding cisplatin to FHX without G-CSF. G-CSF allowed for escalation of HU to 1 g orally every 12 hours without dose-limiting acute toxicity during cycles 1 and 2. Dose-limiting cumulative toxicity consisted of severe or life-threatening myelosuppression and mucositis. To decrease total treatment duration and, thus, cumulative toxicity, a hyperfractionated radiation therapy schedule was investigated using the established chemotherapy doses with 1.5 Gy twice daily on days 1 to 5 (75 Gy over five treatment cycles). No increase in acute toxicities was seen; cumulative toxicities remained frequently severe or life-threatening. Thirty-eight of 45 assessable patients responded. The median survival duration was 12 months for both groups. Median time to treatment failure was 8 months for group 1 and has not been reached for group 2. At 1 year, local control rates were 74% and 91% for groups 1 and 2, respectively. CONCLUSION The addition of cisplatin to 5-FU, HU, and concomitant radiotherapy is feasible using G-CSF. The high locoregional control rate and failure-free interval justify further investigation of this regimen in previously untreated patients.

scholarly journals Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer

2008 ◽  
Vol 99 (3) ◽  
pp. 531-538 ◽  
Author(s):  
Mehmet Gunduz ◽  
Levent Bekir Beder ◽  
Esra Gunduz ◽  
Hitoshi Nagatsuka ◽  
Kunihiro Fukushima ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Mrna Expression ◽  
Neck Cancer ◽  
Poor Prognosis

Alpha B-Crystallin, a New Independent Marker for Poor Prognosis in Head and Neck Cancer

2005 ◽  
Vol 115 (7) ◽  
pp. 1239-1242 ◽  
Author(s):  
David Chin ◽  
Glen M. Boyle ◽  
Rebecca M. Williams ◽  
Kaltin Ferguson ◽  
Nirmala Pandeya ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Poor Prognosis ◽  
Independent Marker

Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer

Head & Neck ◽  
2006 ◽  
Vol 28 (3) ◽  
pp. 225-234 ◽  
Author(s):  
Marjaana Luukkaa ◽  
Pia Vihinen ◽  
Pauliina Kronqvist ◽  
Tero Vahlberg ◽  
Seppo Pyrhönen ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Poor Prognosis ◽  
Expression Levels

Decreasing cytokeratin 17 expression in head and neck cancer predicts nodal metastasis and poor prognosis: The first evidence

2018 ◽  
Vol 43 (4) ◽  
pp. 1010-1018
Author(s):  
E.-S. Xu ◽  
M.-H. Yang ◽  
C.-Y. Liu ◽  
K.-W. Liu ◽  
T.-T. Yang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Poor Prognosis ◽  
Nodal Metastasis ◽  
Cytokeratin 17

scholarly journals C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer

Oncogene ◽  
2018 ◽  
Vol 37 (43) ◽  
pp. 5780-5793 ◽  
Author(s):  
Mei-Chun Lin ◽  
Pin-Hui Chien ◽  
Hsin-Yi Wu ◽  
Syue-Ting Chen ◽  
Hsueh-Fen Juan ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Therapeutic Target ◽  
Poor Prognosis ◽  
Potential Therapeutic Target

scholarly journals Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer

2013 ◽  
Vol 12 (1) ◽  
pp. 124 ◽  
Author(s):  
Victor D Martinez ◽  
Emily A Vucic ◽  
Larissa A Pikor ◽  
Kelsie L Thu ◽  
Roland Hubaux ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Ubiquitin Ligase ◽  
E3 Ubiquitin Ligase ◽  
Multiple Components ◽  
Ubiquitin Ligase Complex ◽  
Genetic Mechanisms
Sign in / Sign up

Export Citation Format

Share Document